Body weight loss of the C26/tk-luc colon carcinoma-bearing mice after treatment with various liposomal drugs.

<p>The mice bearing large tumor (<i>n</i> = 9 for each group, A) and those bearing small tumor (<i>n</i> = 6 for each group, B) were injected intravenously with NanoX (•), InNanoX (▽), NanoVNB (▪) or InVNBL (◊) at 0, 7, and 14 days after first injection (arrow; three injections total). The zero time point indicates the initiation of therapy. Data were expressed as mean ± S.E.M.</p

Survival time of C26/tk-luc colon carcinoma-bearing mice that treated with various liposomal drugs.

*<p>: <i>p</i><0.05,</p>**<p>: <i>p</i><0.01 compared with control group (NanoX).</p

The mean tumor growth inhibition rate of C26/tk-luc colon carcinoma-bearing mice on Day 25 since the 1^st treatment.

a<p>Expected growth inhibition rate = growth inhibition rate of NanoVNB×growth inhibition rate of InNanoX.</p>b<p>Combination index (CI) = expected growth inhibition rate/observed growth inhibition rate.</p>c<p>Combination index larger than 1 indicates a synergistic effect, while that smaller than 1 indicates less than an additive effect.</p

Whole-body scintigraphic images of the C26/tk-luc colon carcinoma-bearing mice at designated time points during the period of treatment with InNanoX and InVNBL.

<p>The scintigraphic imaging was performed for 20 min at 48 h after drugs administration (37 MBq/100 µL per injection) and at 8 days after the last course of treatment. The mice were anesthetized with 1∼3% isoflurane for all imaging. Tumor nodules are indicated by red arrows.</p

Relationship between tumor uptake (%ID/g) and tumor mass at 48 h after administration of InVNBL in mice bearing differently sized C26/tk-luc tumors.

<p>Relationship between tumor uptake (%ID/g) and tumor mass at 48 h after administration of InVNBL in mice bearing differently sized C26/tk-luc tumors.</p

Estimated parameters derived from scintigraphic images of C26/tk-luc colon carcinoma-bearing mice acquired after intravenous injection of ¹¹¹In-containing liposomal drugs InNanoX and InVNBL (37 MBq/100 µL).

a<p>Gamma photon counts per pixel (Counts/pixel) and tumor-to-muscle ratio (T/M) were determined from the ROI of tumor and muscle in the scintigraphic images.</p>b<p>Tumor size (Volume, mean ± S.E.M.) was obtained by calipers measurement.</p

Tumor growth curves of the C26/tk-luc colon carcinoma-bearing mice after treatment with various liposomal drugs.

<p>The mice bearing large tumor (<i>n</i> = 9 for each group, tumor volume 102.4±22.0 mm³, A) and those bearing small tumor (<i>n</i> = 6 for each group, tumor volume 58.4±8.0 mm³, B) were injected intravenously with NanoX (•), InNanoX (▽), NanoVNB (▪) or InVNBL (◊) at 0, 7, and 14 days after first injection (arrow; three injections total). The zero time point indicates the initiation of therapy. Points, mean tumor sizes; bars, S.E.M.</p

<i>In vivo</i> BLI of the C26/tk-luc colon carcinoma-bearing mice after treatment with various liposomal drugs.

<p>The large-tumor mice receiving various liposomal drugs were intraperitoneally injected with 150 mg/kg d-luciferin 15 min prior to image acquisition at designated time points. The photons emitted from the mice (positioned prone) were acquired for 1 minute. The mice were anesthetized with 1∼3% isoflurane while conducting imaging.</p

Survival fraction of the C26/tk-luc colon carcinoma-bearing mice after treatment with various liposomal drugs.

<p>The mice bearing large tumor (<i>n</i> = 9 for each group, A) and those bearing small tumor (<i>n</i> = 6 for each group, B) were injected intravenously with NanoX (•), InNanoX (▽), NanoVNB (▪) or InVNBL (◊) at 0, 7, and 14 days after first injection (arrow; three injections total). Mice were euthanized when tumor volume greater than 2500 mm³.</p

Schematic diagram of liposomal drugs dosing and imaging schedule.

<p>Mice were treated with liposomal drugs (NanoVNB, InNanoX, InVNBL and NanoX as a control) at Day 0, 7 and 14. Scintigraphic imaging of C26/tk-luc colon carcinoma-bearing mice treated with InVNBL was conducted on Day 2, 9, 16 and 22. Bioluminascence imaging was performed on Day 0, 4, 7, 11, 14 and 25.</p